Rani Therapeutics Holdings, Inc. Class A Common Stock
$0.76
-$0.07 (-7.97%)
$0.76Day Range$0.84
Key Statistics
Market Cap
$94.82M
Shares Outstanding
115.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 30, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$0.81
Day High
$0.84
Day Low
$0.76
Volume
1.44M
VWAP
$0.79
Prev Close
$0.82
Transactions
--
Acc. Volume
--
About Rani Therapeutics Holdings, Inc. Class A Common Stock
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
PHARMACEUTICAL PREPARATIONSSIC 283469 employees2051 RINGWOOD AVENUE, SAN JOSE, CA, 95131(408) 457-3700IPO Jul 30, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001856725
- Composite FIGI
- BBG011R6PZ44
- Share Class FIGI
- BBG011R6PZZ0
- Ticker Root
- RANI
- SIC Code
- 2834
About Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) Stock
Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) closed the 2026-09-16 session at $0.76, down 7.97% versus the previous close (-0.07). The stock opened at $0.81 and traded between $0.76 and $0.84 during that session. Session trading volume was 1.4M shares. The volume-weighted average price (VWAP) is $0.79.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Rani Therapeutics Holdings, Inc. Class A Common Stock has a market capitalization of $94.8 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RANI is listed on the XNAS exchange. The company employs approximately 69 people. Rani Therapeutics Holdings, Inc. Class A Common Stock is headquartered in SAN JOSE, CA. The recorded listing date is 2021-07-30.
On this page you can find market RANI stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.